CFO & COO of Heartware International Inc (HTWR, Financial) David Mcintyre sells 2,521 shares of HTWR on 12/07/2009 at an average price of $31.93 a share.
HeartWare International, Inc. along with its subsidiaries is a medical device company focused on developing and commercializing small implantable pumps for the treatment of chronic and end-stage heart failure. Its principle product, the HeartWare Ventricular Assist System, includes a left ventricular assist device, related accessories and surgical tools and is designed to provide circulatory support for patients with advanced heart failure. The company is also developing the Miniaturized Ventricular Assist Device focused on minimally invasive implantation techniques. HeartWare is also developing a portfolio of further miniaturized devices, implantable by progressively less invasive surgery. The Company's corporate headquarters are in Framingham, Massachusetts and its operating and manufacturing activities are based in Miami Lakes, Florida. Heartware International Inc has a market cap of $388.6 million; its shares were traded at around $33.18 with and P/S ratio of 1170.6.
HeartWare International, Inc. along with its subsidiaries is a medical device company focused on developing and commercializing small implantable pumps for the treatment of chronic and end-stage heart failure. Its principle product, the HeartWare Ventricular Assist System, includes a left ventricular assist device, related accessories and surgical tools and is designed to provide circulatory support for patients with advanced heart failure. The company is also developing the Miniaturized Ventricular Assist Device focused on minimally invasive implantation techniques. HeartWare is also developing a portfolio of further miniaturized devices, implantable by progressively less invasive surgery. The Company's corporate headquarters are in Framingham, Massachusetts and its operating and manufacturing activities are based in Miami Lakes, Florida. Heartware International Inc has a market cap of $388.6 million; its shares were traded at around $33.18 with and P/S ratio of 1170.6.
Insiders' Positions with HTWR
- Sell:: CFO & COO David Mcintyre sold 1,580 shares of HTWR stock on 12/03/2009 at the average price of 31.63, the price of the stock has increased by 4.9% since
- Sell:: CFO & COO David Mcintyre sold 3,400 shares of HTWR stock on 11/30/2009 at the average price of 32.04, the price of the stock has increased by 3.56% since
- Sell:: CFO & COO David Mcintyre sold 3,415 shares of HTWR stock on 11/24/2009 at the average price of 32.21, the price of the stock has increased by 3.01% since
- Sell:: CFO & COO David Mcintyre sold 1,000 shares of HTWR stock on 11/16/2009 at the average price of 32.17, the price of the stock has increased by 3.14% since
- Sell:: CFO & COO David Mcintyre sold 1,076 shares of HTWR stock on 07/17/2009 at the average price of 22.59, the price of the stock has increased by 46.88% since
Insiders' Positions with HTWR
- Buy:: 10% Owner Muneer A Satter bought 3 shares of HTWR stock on 08/13/2009 at the average price of 23.79, the price of the stock has increased by 39.47% since
- Sell:: VP, Finance Lauren Farrell sold 407 shares of HTWR stock on 12/03/2009 at the average price of 31.52, the price of the stock has increased by 5.27% since
- Sell:: Chief Scientifc Officer Jeffrey Larose sold 1,598 shares of HTWR stock on 12/03/2009 at the average price of 31.56, the price of the stock has increased by 5.13% since
- Sell:: Chief Scientifc Officer Jeffrey Larose sold 3,476 shares of HTWR stock on 11/30/2009 at the average price of 32.01, the price of the stock has increased by 3.66% since
- Sell:: Chief Scientifc Officer Jeffrey Larose sold 3,393 shares of HTWR stock on 11/24/2009 at the average price of 32.18, the price of the stock has increased by 3.11% since
